stoxline Quote Chart Rank Option Currency Glossary
Molecular Templates, Inc. (MTEM)
4.81  -0.17 (-3.41%)    11-29 10:10
Open: 5.05
High: 5.05
Volume: 1,149
Pre. Close: 4.98
Low: 4.81
Market Cap: 26(M)
Technical analysis
2023-11-29 10:48:28 AM
Short term     
Mid term     
Targets 6-month :  6.7 1-year :  7.55
Resists First :  5.74 Second :  6.46
Pivot price 5.15
Supports First :  4.55 Second :  3.79
MAs MA(5) :  4.98 MA(20) :  5.13
MA(100) :  7.06 MA(250) :  6.86
MACD MACD :  -0.3 Signal :  -0.4
%K %D K(14,3) :  12.8 D(3) :  18.3
RSI RSI(14): 37.9
52-week High :  9.6 Low :  4.55
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ MTEM ] has closed above bottom band by 20.1%. Bollinger Bands are 29% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.37 - 5.4 5.4 - 5.42
Low: 4.85 - 4.88 4.88 - 4.9
Close: 4.91 - 4.95 4.95 - 4.99
Company Description

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Headline News

Mon, 13 Nov 2023
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update - Yahoo Finance

Thu, 02 Nov 2023
Molecular Templates Announces First Patient Dosed in Phase 1 ... - BioSpace

Fri, 11 Aug 2023
Molecular Templates Announces 1-for-15 Reverse Stock Split - Yahoo Finance

Tue, 01 Aug 2023
Solu Therapeutics Debuts with $31 Million in Seed Funding to ... - Business Wire

Thu, 13 Jul 2023
Molecular Templates Announces Up to $40 Million Private ... - GlobeNewswire

Tue, 11 Apr 2023
Molecular Templates to cut 50% of staff; Austin co. pursues 'strategic ... - The Business Journals

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 5 (M)
Shares Float 4 (M)
Held by Insiders 0 (%)
Held by Institutions 0 (%)
Shares Short 66 (K)
Shares Short P.Month 58 (K)
Stock Financials
EPS -6.93
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.25
Profit Margin -49.6 %
Operating Margin -75.6 %
Return on Assets (ttm) -20.1 %
Return on Equity (ttm) -478.9 %
Qtrly Rev. Growth 60.2 %
Gross Profit (p.s.) 0
Sales Per Share 9.85
EBITDA (p.s.) -3.5
Qtrly Earnings Growth 0 %
Operating Cash Flow -55 (M)
Levered Free Cash Flow -32 (M)
Stock Valuations
PE Ratio -0.7
PEG Ratio -0.4
Price to Book value 3.81
Price to Sales 0.48
Price to Cash Flow -0.47
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android